Enterprise
Making Malaysia a clinical blood test hub
Sharina Ahmad | 03 May 2019 00:30
InterVenn BioSciences, a biotech company, hopes to establish Malaysia as a hub in the Asia-Pacific region for clinical blood-based tests for early detection of cancer and major chronic diseases.

Headquartered in Silicon Valley, USA, the company has chosen Malaysia to set up its subsidiary, which is the first in Asia to start and develop early detection for the ovarian cancer blood test using artificial intelligence (AI) and next-gen mass spectrometry. It started with an initial investment of RM39 mil in December last year.

The investment was led by San Francisco-based biotech investor Genoa Ventures, with participation from True Ventures, Amplify Partners, Boost VC, and Prado SV.

Download and read more in the latest issue of Focus Malaysia here:
Snippets
AirAsia X Delivers Strong Operating Cashflow

Commendable core performance excluding one-offs in a seasonally weak quarter.


ELK-Desa First Quarter Profit Rises 15%

ELK-Desa Resources Berhad registered a strong start to its 2020 financial year.